相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating
Jodi E. Gresack et al.
PSYCHOPHARMACOLOGY (2014)
Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor
Tetsuaki Hiyoshi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats
O. A. H. Reneerkens et al.
BEHAVIOURAL BRAIN RESEARCH (2013)
Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801
Olga A. H. Reneerkens et al.
BEHAVIOURAL BRAIN RESEARCH (2013)
An agonist at glutamate and dopamine D2 receptors, LY404039
Philip Seeman
NEUROPHARMACOLOGY (2013)
Differential Role of NR2A and NR2B Subunits in N-Methyl-D-Aspartate Receptor Antagonist-Induced Aberrant Cortical Gamma Oscillations
Bernat Kocsis
BIOLOGICAL PSYCHIATRY (2012)
Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia
Kara Kittelberger et al.
BRAIN STRUCTURE & FUNCTION (2012)
Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power
Nigel C. Jones et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
Gamma synchrony: Towards a translational biomarker for the treatment-resistant symptoms of schizophrenia
Michael J. Gandal et al.
NEUROPHARMACOLOGY (2012)
Cognition in schizophrenia: core psychological and neural mechanisms
Deanna M. Barch et al.
TRENDS IN COGNITIVE SCIENCES (2012)
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
Jose L. Moreno et al.
NEUROSCIENCE LETTERS (2011)
Evidence of abnormalities in mid-latency auditory evoked responses (MLAER) in cognitive subtypes of patients with schizophrenia
Shahrzad Mazhari et al.
PSYCHIATRY RESEARCH (2011)
Abnormal neural oscillations and synchrony in schizophrenia
Peter J. Uhlhaas et al.
NATURE REVIEWS NEUROSCIENCE (2010)
Increased Hippocampal, Thalamic, and Prefrontal Hemodynamic Response to an Urban Noise Stimulus in Schizophrenia
Jason R. Tregellas et al.
AMERICAN JOURNAL OF PSYCHIATRY (2009)
Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
Steven M. Grauer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
P50, N100, and P200 sensory gating: Relationships with behavioral inhibition, attention, and working memory
Marijn Lijffijt et al.
PSYCHOPHYSIOLOGY (2009)
Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients
Nash N. Boutros et al.
SCHIZOPHRENIA RESEARCH (2009)
N-methyl d-aspartate receptor antagonists ketarnine and MK-801 induce wake-related aberrant,γ oscillations in the rat neocortex
Didier Pinault
BIOLOGICAL PSYCHIATRY (2008)
gamma-band auditory steady-state responses are impaired in first episode psychosis
Kevin M. Spencer et al.
BIOLOGICAL PSYCHIATRY (2008)
Sensory gating: A translational effort from basic to clinical science
Howard C. Cromwell et al.
CLINICAL EEG AND NEUROSCIENCE (2008)
Antipsychotic-like properties of phosphodiesterase 4 inhibitors: Evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle
T. B. Halene et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia
C. J. Schmidt et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats
W. Dimpfel
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats
Jingyi Ma et al.
PSYCHOPHARMACOLOGY (2007)
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist:: In vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
Linda M. Rorick-Kehn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma
J. M. Phillips et al.
NEUROSCIENCE (2007)
EEG alpha oscillations: The inhibition-timing hypothesis
Wolfgang Klimesch et al.
BRAIN RESEARCH REVIEWS (2007)
Neural synchrony in brain disorders: Relevance for cognitive dysfunctions and pathophysiology
Peter J. Uhhaas et al.
NEURON (2006)
Cognitive dysfunction in schizophrenia -: Convergence of γ-aminobutyric acid and glutamate alterations
David A. Lewis et al.
ARCHIVES OF NEUROLOGY (2006)
Prepulse inhibition and P50 suppression: Commonalities and dissociations
Bob Oranje et al.
PSYCHIATRY RESEARCH (2006)
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function
Judith A. Siuciak et al.
NEUROPHARMACOLOGY (2006)
Inhibition of the striatum-enriched phosphodiesterase PDEIOA: A novel approach to the treatment of psychosis
Judith A. Siuciak et al.
NEUROPHARMACOLOGY (2006)
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
Z Xie et al.
NEUROSCIENCE (2006)
Human EEG gamma oscillations in neuropsychiatric disorders
CS Herrmann et al.
CLINICAL NEUROPHYSIOLOGY (2005)
A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity
R Galici et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Contributions of subtype and spectral frequency analyses to the study of P50 ERP amplitude and suppression in schizophrenia
JK Johannesen et al.
SCHIZOPHRENIA RESEARCH (2005)
Early-stage visual processing deficits in schizophrenia
PD Butler et al.
CURRENT OPINION IN PSYCHIATRY (2005)
Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials
SJ Siegel et al.
NEUROSCIENCE (2005)
Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential
CR Maxwell et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Midlatency auditory event-related potentials in mice: Comparison to midlatency auditory ERPs in humans
D Umbricht et al.
BRAIN RESEARCH (2004)
Neural synchrony indexes disordered perception and cognition in schizophrenia
KM Spencer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Attention and awareness in synchrony
C. Tallon-Baudry
TRENDS IN COGNITIVE SCIENCES (2004)
Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications
CR Maxwell et al.
NEUROSCIENCE (2004)
Pre-attentive processing and schizophrenia: animal studies
BA Ellenbroek
PSYCHOPHARMACOLOGY (2004)
Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains
PM Connolly et al.
BRAIN RESEARCH (2003)
Ear of stimulation determines schizophrenia-normal brain activity differences in an auditory paired-stimuli paradigm
BA Clementz et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Immunohistochemical localization of PDE10A in the rat brain
TF Seeger et al.
BRAIN RESEARCH (2003)
Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism
JK Simosky et al.
PSYCHOPHARMACOLOGY (2003)
Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia
WA Phillips et al.
BEHAVIORAL AND BRAIN SCIENCES (2003)
Synchronous Gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia
KH Lee et al.
BRAIN RESEARCH REVIEWS (2003)
Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodrome
KS Cadenhead
PSYCHIATRIC CLINICS OF NORTH AMERICA (2002)
Effects of ketamine in normal and schizophrenic volunteers
AC Lahti et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Response to the first stimulus determines reduced auditory evoked response suppression in schizophrenia: single trials analysis using MEG
LD Blumenfeld et al.
CLINICAL NEUROPHYSIOLOGY (2001)
Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges
NR Swerdlow et al.
PSYCHOPHARMACOLOGY (2001)
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
MA Geyer et al.
PSYCHOPHARMACOLOGY (2001)
Deficits in auditory and visual context-dependent processing in schizophrenia -: Defining the pattern
DC Javitt et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine
J Cartmell et al.
PSYCHOPHARMACOLOGY (2000)
Effects of temporal variability on P50 and the gating ratio in schizophrenia - A frequency domain adaptive filter single-trial analysis
JV Patterson et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder
KS Cadenhead et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients?
GA Light et al.
BIOLOGICAL PSYCHIATRY (2000)
分享论文
